Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Victor L Serebruany

Showing results (1-10 of 195) with videos related to

Pageof 20
Sort By:
Cardiology|February 10, 2011
Aspirin dose and ticagrelor benefit in PLATO: fact or fiction?Victor L Serebruany
Circulation|August 25, 2010
Letter by Serebruany regarding article, "Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38"Victor L Serebruany
Cardiology|January 8, 2011
Mortality benefit in PLATO cannot be explained by antiplatelet properties of ticagrelorVictor L Serebruany
International Journal of Cardiology|July 1, 2015
Redesigning TRACER trial after TRITONVictor L Serebruany
European Heart Journal|June 28, 2006
Prasugrel, clopidogrel, and combining Swedish apples with American orangesVictor L Serebruany
American Journal of Therapeutics|June 18, 2009
Late prasugrel benefit in STEMI patients?Victor L Serebruany
The American Journal of Cardiology|September 11, 2007
The "clopidogrel resistance" trapVictor L Serebruany
Thrombosis Research|May 3, 2008
Plasma clopidogrel metabolites and antiplatelet "resistance": back to the futureVictor L Serebruany
Polskie Archiwum Medycyny Wewnetrznej|October 5, 2016
The moving target of clopidogrel response variability: new tricks of the old dog?Victor L Serebruany
The American Journal of Medicine|January 31, 2006
Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something?Victor L Serebruany
Pageof 20

Showing results (1-10 of 195) with videos related to

Sort By:
Pageof 20
Cardiology|February 10, 2011
Aspirin dose and ticagrelor benefit in PLATO: fact or fiction?Victor L Serebruany
Circulation|August 25, 2010
Letter by Serebruany regarding article, "Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38"Victor L Serebruany
Cardiology|January 8, 2011
Mortality benefit in PLATO cannot be explained by antiplatelet properties of ticagrelorVictor L Serebruany
International Journal of Cardiology|July 1, 2015
Redesigning TRACER trial after TRITONVictor L Serebruany
European Heart Journal|June 28, 2006
Prasugrel, clopidogrel, and combining Swedish apples with American orangesVictor L Serebruany
American Journal of Therapeutics|June 18, 2009
Late prasugrel benefit in STEMI patients?Victor L Serebruany
The American Journal of Cardiology|September 11, 2007
The "clopidogrel resistance" trapVictor L Serebruany
Thrombosis Research|May 3, 2008
Plasma clopidogrel metabolites and antiplatelet "resistance": back to the futureVictor L Serebruany
Polskie Archiwum Medycyny Wewnetrznej|October 5, 2016
The moving target of clopidogrel response variability: new tricks of the old dog?Victor L Serebruany
The American Journal of Medicine|January 31, 2006
Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something?Victor L Serebruany
Pageof 20